Startup focused on B-cell therapies launched with $52M in Series A
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
RDMD raises $14M for rare disease real-world evidence generation
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
What sparks the investment passions of David Shaywitz of Takeda Ventures? (Q&A)
The Takeda Ventures Senior Partner will take part in the panel discussion Trends in Oncology Investing at the MedCity CONVERGE Conference July 11-12 in Philadelphia.
In a busy field, biotech incubators are evolving
Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.
Three “hits” on biopharma market trends at mcINVEST
From money-back guarantees to a surprising source of funding, MedCity INVEST presenters and panelists discussed some of the major trends influencing the biopharma sector in 2017.
VCs, corporate pharma investors put $38M behind Naurex’s new treatments for depression
If there’s any truth to the notion that corporate VC-backed companies have a higher rate of overall success than those without corporate VC funding, here’s a company we should be keeping an eye on. Naurex Inc., a young pharmaceutical company focused on psychiatry and neurology, rounded up $38 million from lead investor Baxter Ventures and […]
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.